Deep-dive briefing

Sat · 26 Sep 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

Phase 2 Evidence and Impact Analysis

All articles are peer-reviewed, abstract-only access. No preprints in this batch. Conservative scoring applied where classification_confidence = medium or sample size is limited.

Article 1 — Lonial et al. — EXCALIBER-RRMM Phase 3 | PMID 42790445

Iberdomide + daratumumab + dexamethasone vs. DVd in relapsed/refractory MM

Dimension	Score	Rationale
Scientific Novelty	7	Iberdomide (CELMoD) is a mechanistically distinct class from prior IMiDs; head-to-head vs. DVd in 1–2 prior lines is a meaningful design
Clinical Relevance	8	Directly addresses a large RRMM population; phase 3 data in a high-value therapeutic niche
Population Reach	7	~176,000 new MM cases/year globally; 1–2 prior line RRMM is a substantial subgroup
Implementation Speed	6	Regulatory review pathway exists; pending full data publication and approval
Evidence Strength	8	Phase 3 RCT, 939 randomized; high confidence classification; abstract-only limits full assessment

Key quantitative result: 939 patients randomized (279 stage 1, 660 stage 2); PFS/ORR data not yet extractable from abstract
External validation: This is the pivotal trial; no independent replication yet
Main limitation: Abstract-only — primary endpoint results (PFS) and OS data not accessible; open-label design
Equity: Globally enrolled (Asia, Europe, Americas); transplant-ineligible patients not explicitly specified as inclusion criterion — equity implications unclear pending full paper
Evidence Maturity: Validated (Phase 3 RCT; upgrades from triage "Exploratory")
Original triage_score: 7 | Phase 2 composite: 7.3

Article 2 — Wang et al. — CBC+CPD ML model for NHL triage | PMID 42790934

SVM model from routine CBC + cell population data for NHL inpatient risk stratification

Dimension	Score	Rationale
Scientific Novelty	5	ML applied to CBC is active territory; CPD parameters add incremental novelty
Clinical Relevance	6	Useful triage tool for NHL inpatients; single-center, modest AUC in validation set
Population Reach	5	NHL is moderately common (~80,000 US cases/year) but model is inpatient-specific
Implementation Speed	6	CBC analyzers already collect CPD in many centers; software integration feasible
Evidence Strength	5	Cohort study, n=510, internal validation AUC 0.803; no external validation reported

Key quantitative result: Training AUC=0.894; validation AUC=0.803 (95% CI 0.858–0.923 training)
External validation: Not reported; internal validation only
Main limitation: Single institution, no prospective or external validation; AUC degradation from training to validation (~10 points) warrants caution
Equity: No mention of demographic or geographic equity considerations
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 7 | Phase 2 composite: 5.5

Article 3 — Chen et al. — Habitat imaging CT/PET-CT systematic review | PMID 42789168

21 studies, 7,363 patients; HI for tumor heterogeneity characterization

Dimension	Score	Rationale
Scientific Novelty	6	Habitat imaging is an emerging field; systematic synthesis adds value but not groundbreaking
Clinical Relevance	5	Primarily a research tool; not yet a clinical standard; prospective validation explicitly lacking
Population Reach	6	Applicable across multiple solid tumor types
Implementation Speed	4	Requires prospective trials before clinical adoption; imaging infrastructure gap
Evidence Strength	6	Systematic review of 21 studies, 7,363 patients; quality depends on included study heterogeneity

Key quantitative result: 21 studies, 7,363 patients; specific diagnostic performance metrics not in abstract
External validation: Authors explicitly note prospective validation is needed
Main limitation: HI not yet validated as a clinical biomarker; likely heterogeneous included studies
Equity: No equity discussion evident
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 7 | Phase 2 composite: 5.4

Article 4 — Zadeh et al. — CAR-T in Glioma Meta-analysis | PMID 42791198 🟠

12 studies, 153 evaluable patients; pooled ORR 16.9%

Dimension	Score	Rationale
Scientific Novelty	7	CAR-T in CNS tumors is frontier territory; BBB penetration and immunosuppressive TME make this a high-novelty problem
Clinical Relevance	6	GBM has near-zero durable responses to standard therapy; even modest CAR-T activity is clinically meaningful
Population Reach	5	~310,000 new glioma cases/year globally; all are high unmet need
Implementation Speed	3	Manufacturing complexity, CNS delivery barriers, regulatory requirements; 5–10+ years to broad adoption
Evidence Strength	6	Meta-analysis of early-phase trials; only 153 evaluable patients; wide CIs on ORR

Key quantitative result: Pooled ORR 16.9% (95% CI 8.0%–32.2%); CR rate 8.1% (95% CI 3.5%–17.8%)
External validation: Meta-analysis of existing trials; no independent replication of individual studies
Main limitation: Very small pooled n (153); early-phase heterogeneous trials; publication bias likely; wide confidence intervals
Equity: Access to CAR-T is severely limited by cost and manufacturing infrastructure globally
Evidence Maturity: Exploratory (confirmed; wide CIs, small n preclude "Validated")
Original triage_score: 7 | Phase 2 composite: 5.5

Article 5 — Goyal et al. — IBS-like symptoms in quiescent IBD meta-analysis | PMID 42790835

13 RCTs, n=688; dietary, gut-brain, and psychological interventions

Dimension	Score	Rationale
Scientific Novelty	5	IBS-IBD overlap is recognized; dietary interventions studied before; synthesis adds modest value
Clinical Relevance	7	Up to 1/3 of IBD patients in remission affected; major unmet need; addresses a common clinical dilemma
Population Reach	7	~3 million IBD patients in US alone; 1 million+ with quiescent disease + persistent symptoms
Implementation Speed	6	Dietary interventions are low-cost and immediately accessible; heterogeneity limits guideline adoption
Evidence Strength	5	13 RCTs but very low certainty evidence (I²=90% for dietary arm); heterogeneous interventions

Key quantitative result: Dietary SMD –1.33 (95% CI –4.42 to 1.77); I²=90% — very high uncertainty
External validation: Meta-analysis of RCTs; high heterogeneity undermines effect size confidence
Main limitation: Extreme statistical heterogeneity; "very low certainty" per abstract; imprecision
Equity: Dietary interventions are relatively accessible and low-cost; broadly applicable
Evidence Maturity: Exploratory (confirmed; very low certainty GRADE)
Original triage_score: 7 | Phase 2 composite: 6.0

Article 6 — El Jurdi et al. — Clobetasol for oral cGVHD RCT | PMID 42790417

Phase 2 RCT, n=40; ORR 91% at day 28

Dimension	Score	Rationale
Scientific Novelty	6	Topical clobetasol for oral cGVHD is not entirely new concept, but RCT-level evidence is scarce
Clinical Relevance	8	Oral cGVHD is debilitating; 91% ORR (19% CR, 72% PR) is a strong signal with immediate clinical utility
Population Reach	5	~15,000 allogeneic HSCT patients/year in US; ~40–70% develop cGVHD; oral cGVHD is common subset — meaningful within rare disease context
Implementation Speed	8	Clobetasol is an off-the-shelf topical; low regulatory and cost barriers; near-term adoptable
Evidence Strength	6	Randomized, placebo-controlled phase 2; n=40, only 35 reached day 28; small but rigorous design

Key quantitative result: ORR 91% (CR 19%, PR 72%, SD 9%) at day 28
External validation: No independent replication; single phase 2 trial
Main limitation: Very small sample (n=35 analyzable); short follow-up (28 days); durability of response unknown
Equity: Clobetasol solution is inexpensive and widely available in most healthcare settings
Evidence Maturity: Exploratory → trending Validated within its narrow indication; Phase 3 needed
Original triage_score: 7 | Phase 2 composite: 6.7

Article 7 — Carter et al. — ADAMTS13 Variant Database for cTTP | PMID 42789934

385 ADAMTS13 variants curated into interactive database

Dimension	Score	Rationale
Scientific Novelty	6	Comprehensive curation of 385 variants into an accessible, expandable database is a meaningful contribution
Clinical Relevance	6	Directly aids variant interpretation in cTTP; supports clinical decision-making in a rare but life-threatening disease
Population Reach	3	cTTP affects ~1–2 per million; very rare disease but with severe unmet need
Implementation Speed	8	Database is already accessible; no regulatory hurdles; immediately usable by clinicians/labs
Equity	—	Open online database lowers global access barriers; benefits underdiagnosed populations
Evidence Strength	5	Observational/literature review; medium classification confidence; no prospective validation

Key quantitative result: 385 variants identified across literature; molecular heterogeneity characterized
External validation: Curated from existing literature; not a prospective trial
Main limitation: Medium confidence classification; database utility depends on completeness and updating cadence; variant pathogenicity calls require functional validation
Equity: Freely accessible online database; benefits clinicians in low-resource settings disproportionately
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 7 | Phase 2 composite: 5.5

Article 8 — Raeissadat et al. — PRP vs. Collagen vs. HA in Knee OA RCT | PMID 42791219

n=126 completed; 3-arm RCT, WOMAC at 6 months

Dimension	Score	Rationale
Scientific Novelty	5	PRP vs. HA comparison is well-studied; hydrolyzed collagen arm adds modest novelty
Clinical Relevance	7	Knee OA affects hundreds of millions; intra-articular therapy choice has direct clinical impact
Population Reach	9	Knee OA is one of the most prevalent musculoskeletal conditions globally (>500M affected)
Implementation Speed	6	All three agents exist; clinical integration depends on comparative superiority signal
Evidence Strength	6	RCT, n=126 completers, 6-month follow-up; all groups improved (p<0.001) but head-to-head differences not specified in abstract

Key quantitative result: All groups improved significantly (p<0.001); no between-group delta in abstract
Main limitation: Abstract doesn't report which arm was superior; results interpretation limited; single center
Equity: All three treatments vary widely in cost and availability globally
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 7 | Phase 2 composite: 6.5

Article 9 — Lin et al. — TCM + HIFU for Adenomyosis pilot RCT | PMID 42788264

n=66, pilot RCT; VAS scores lower in observation group

Dimension	Score	Rationale
Scientific Novelty	6	TCM + HIFU combination is novel in adenomyosis; integration of traditional and modern modalities
Clinical Relevance	5	Adenomyosis is underdiagnosed; VAS improvement is patient-relevant but a surrogate outcome
Population Reach	6	Adenomyosis affects ~10–15% of reproductive-age women; substantial unmet need
Implementation Speed	4	HIFU requires specialized equipment; TCM standardization and regulatory approval are barriers
Evidence Strength	5	Pilot RCT, n=66; not powered for definitive conclusions; limited mechanistic detail

Key quantitative result: VAS scores significantly lower in observation group vs. control (p<0.05); magnitude not in abstract
Main limitation: Small pilot study; TCM cocktail composition variability; blinding limited; mechanism speculative
Equity: HIFU access is geographically and economically restricted
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 7 | Phase 2 composite: 5.2

Article 10 — Baccon et al. — Chemoradiotherapy in limited-stage MCL, NCDB | PMID 42787875

n=2,428; OS 11.2 vs. 7.4 years (chemo+RT vs. chemo alone)

Dimension	Score	Rationale
Scientific Novelty	6	Limited-stage MCL is understudied; NCDB analysis providing OS signal for combined modality is novel
Clinical Relevance	7	~3.8-year OS advantage for combined modality is clinically substantial in a disease where data are sparse
Population Reach	4	MCL is rare (~4,000 US cases/year); limited-stage is a minority subset
Implementation Speed	6	Chemoradiotherapy infrastructure exists; needs prospective confirmation before standard adoption
Evidence Strength	5	NCDB cohort study; selection bias, treatment heterogeneity, and unmeasured confounders are major concerns

Key quantitative result: Median OS 11.2 vs. 7.4 vs. 8.0 years (chemo+RT vs. chemo alone vs. RT alone; P<0.001)
External validation: NCDB-based; no prospective validation
Main limitation: Retrospective NCDB; no information on rituximab use, molecular subtype, performance status; selection bias
Equity: Radiation access disparities could exacerbate equity gaps in limited-stage MCL
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.6

Article 11 — Usmani et al. — DVRd in transplant-ineligible NDMM, CEPHEUS subgroup | PMID 42789828

Phase 3 subgroup, n=395; sustained MRD negativity doubled with DVRd

Dimension	Score	Rationale
Scientific Novelty	6	Daratumumab-based quadruplets are established; MRD-negativity durability data add meaningful precision
Clinical Relevance	8	Transplant-ineligible NDMM is a major, underserved subgroup; sustained MRD negativity is an emerging surrogate for OS
Population Reach	7	~35,000 new MM cases/year in US; majority are transplant-ineligible/deferred
Implementation Speed	6	DVRd is already approved; MRD testing integration is the remaining barrier
Evidence Strength	7	Pre-specified subgroup of a phase 3 RCT (NCT03652064); subgroup caveats apply but design is robust

Key quantitative result: Sustained MRD negativity ≥12 months: 47.2% vs. 28.3% (P=.0010); ≥24 months: 40.3% vs. 22.8% (P=.0015)
External validation: Phase 3 trial; subgroup analysis; primary trial results published separately
Main limitation: Subgroup analysis; OS data not reported in abstract; MRD as surrogate endpoint not yet OS-validated in all MM contexts
Equity: DVRd is expensive; access disparate in low/middle-income countries
Evidence Maturity: Validated (Phase 3 subgroup; pre-specified)
Original triage_score: 6 | Phase 2 composite: 7.0

Article 12 — Wu et al. — BCI-Robot vs. Conventional Rehab for Stroke, NMA | PMID 42789169

23 cohorts, 727 participants; FMA-UE primary outcome

Dimension	Score	Rationale
Scientific Novelty	6	BCI-coupled robotics is genuinely novel rehabilitation technology
Clinical Relevance	6	Upper limb stroke recovery is a major clinical need; network meta-analysis adds comparability
Population Reach	8	~15 million strokes/year globally; upper limb impairment affects ~80%
Implementation Speed	3	BCI-robot systems require specialized equipment, training, cost; widespread adoption is 5–10 years away
Evidence Strength	6	NMA of 22 cohorts, 727 participants; consistency model adopted; no significant inconsistency

Key quantitative result: No significant inconsistency in NMA; BCI-robot comparable to conventional therapy (specific effect sizes not in abstract)
Main limitation: NMA with heterogeneous rehabilitation protocols; small individual trial sizes; abstract doesn't specify BCI-robot superiority
Note: Matched to "Hematologic malignancies" in triage — appears to be a classification error by OpenClaw
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.8

Article 13 — Karp et al. — Community Need Priority Index for Breast Cancer Screening | PMID 42789831 🔴

n=243 census tracts; CNPI-BCS AUC 0.692 corrected

Dimension	Score	Rationale
Scientific Novelty	5	Community need indices exist; application to breast cancer screening resource allocation has implementation value
Clinical Relevance	6	Identifies highest-need communities; supports screening equity; AUC is modest
Population Reach	8	Breast cancer affects 1 in 8 women in US; underscreened communities are large and diverse
Implementation Speed	7	Index is a data-linkage tool; could be adopted by cancer centers immediately with EHR/census data
Evidence Strength	5	Single-institution cohort study; corrected AUC 0.692 is adequate but not strong; needs multi-site validation

Key quantitative result: Corrected AUC=0.692; top CNPI-BCS quintile captured 45% of events and 44% of patients screened
Main limitation: Single institution; AUC does not exceed 0.74 even uncorrected; generalizability to diverse cancer centers unclear
Equity: This study is explicitly designed to benefit underserved communities — strong equity orientation 🟡
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 6.1

Article 14 — Jiang et al. — Weakly supervised 3D medical image segmentation | PMID 42787768

Probabilistic-aware DL for 3D segmentation; no clinical population

Dimension	Score	Rationale
Scientific Novelty	6	Weakly supervised segmentation addresses annotation bottleneck; probabilistic framing is methodologically interesting
Clinical Relevance	4	No clinical validation; performance metrics not tied to patient outcomes
Population Reach	3	Indirect; depends on downstream clinical application
Implementation Speed	3	Requires clinical validation and integration; long pipeline to adoption
Evidence Strength	3	No clinical population; unknown species/dataset; medium confidence classification

Key quantitative result: Not specified in abstract
Main limitation: No clinical population; no patient-level validation; abstract-only
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 3.8

Article 15 — Lee et al. — AI coronary artery analysis in ED, multicenter | PMID 42791089

n=1,193; sensitivity 79.5%, NPV 95.4% for obstructive CAD

Dimension	Score	Rationale
Scientific Novelty	5	AI-assisted CCTA interpretation in ED is an active area; multicenter data adds credibility
Clinical Relevance	7	High NPV (95.4%) is clinically actionable for ED rule-out of obstructive CAD; could reduce unnecessary invasive workup
Population Reach	8	Chest pain is among the most common ED presentations globally
Implementation Speed	6	On-premise AI software exists; hospital IT integration and FDA/CE clearance are rate-limiting
Evidence Strength	6	Multicenter cohort, n=1,193; sensitivity 79.5% (moderate); NPV 95.4% (strong for rule-out)

Key quantitative result: Sensitivity 79.5%, NPV 95.4% vs. expert consensus
Main limitation: Open-label cohort; no prospective RCT; sensitivity below 80% may miss significant disease; reference standard is expert consensus, not invasive angiography
Equity: ED populations include underserved patients; AI tool could democratize specialist-level interpretation
Evidence Maturity: Exploratory (confirmed; needs RCT-level evidence before adoption)
Original triage_score: 6 | Phase 2 composite: 6.3

Article 16 — Alfieri et al. — AI in perioperative pain scoping review protocol | PMID 42790900

Protocol only; no results

Dimension	Score	Rationale
Scientific Novelty	4	Protocol for a scoping review; no findings yet
Clinical Relevance	4	Topic is relevant but no data to evaluate
Population Reach	6	Perioperative pain affects all surgical patients
Implementation Speed	2	Protocol only; findings years away
Evidence Strength	2	Protocol publication; no results

Evidence Maturity: Exploratory (pre-results)
Original triage_score: 6 | Phase 2 composite: 3.7

Article 17 — Martinez-Zujeros et al. — Predictive factors for functional recovery in older inpatients | PMID 42790865

Retrospective, n=957; mean age 82.4 years

Dimension	Score	Rationale
Scientific Novelty	4	Prognostic modeling in geriatric rehabilitation is established; this adds incremental data
Clinical Relevance	6	Identifies predictors for rehabilitation outcome in elderly; directly informs clinical decision-making
Population Reach	7	Geriatric rehabilitation affects millions globally; aging population makes this increasingly important
Implementation Speed	5	Multivariable models can be implemented relatively quickly; external validation needed
Evidence Strength	5	Retrospective, n=957; inconsistent biomarker associations noted in abstract

Key quantitative result: Mean age 82.4 years; specific predictive model performance metrics not in abstract
Main limitation: Retrospective; inconsistent biomarker associations; single institution likely
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.4

Article 18 — Maheshwari et al. — LncRNAs and the Cancer Epitranscriptome | PMID 42790864

Narrative/mechanistic review; no patient data

Dimension	Score	Rationale
Scientific Novelty	6	lncRNA-epitranscriptome intersection is frontier basic science
Clinical Relevance	3	Mechanistic review; no clinical data; patient benefit is distant
Population Reach	2	Indirect; no clinical population
Implementation Speed	2	Basic science to clinical application typically 10+ years
Evidence Strength	3	Observational/mechanistic review; medium confidence; no patient data

Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 3.2

Article 19 — Casolino et al. — Lancet Oncology Commission on Equitable Cancer Genomics | PMID 42790448

Global commission report; millions without guideline-indicated genomic interventions

Dimension	Score	Rationale
Scientific Novelty	5	Equity gaps in cancer genomics are documented; commission synthesizes and proposes framework
Clinical Relevance	7	Directly calls for policy and implementation change; affects millions of cancer patients
Population Reach	9	Global scope; all cancer patients potentially affected by precision oncology access inequity
Implementation Speed	4	Policy-level change is slow; infrastructure and financing barriers are substantial
Evidence Strength	4	Commission report / observational synthesis; medium confidence; not an interventional study

Key quantitative result: "Millions of patients without guideline-indicated interventions each year" — no specific number in abstract
Main limitation: Commission report; no primary data; implementation pathway not fully operationalized
Equity: This article is explicitly about equity — landmark 🟡 equity framing
Evidence Maturity: Exploratory (confirmed; policy-level)
Original triage_score: 6 | Phase 2 composite: 5.9

Article 20 — Huang et al. — PD-L1 vs. 5-variable genomic-immunotherapy score | PMID 42790332

n=286; composite AUC 0.698 vs. PD-L1 0.657 (P=0.42, no difference)

Dimension	Score	Rationale
Scientific Novelty	5	Composite biomarker vs. PD-L1 for ICI prediction is a common research question
Clinical Relevance	6	Null result is informative: composite adds no benefit over PD-L1; simplifies practice
Population Reach	7	ICI use is broad across tumor types; biomarker selection affects all ICI candidates
Implementation Speed	5	Null result supports existing practice (PD-L1 alone); no new test needed
Evidence Strength	5	Real-world cohort, n=286 (102 efficacy-evaluable); ORR 47.1%; single-center

Key quantitative result: AUC 0.698 (composite) vs. 0.657 (PD-L1; DeLong P=0.42, no difference)
Main limitation: Small efficacy-evaluable cohort (n=102); retrospective; single institution; species/population unclear
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.6

Article 21 — Lucía-Gozálvez et al. — METLUNG metabolomic profiling for NSCLC immunotherapy | PMID 42791035

n=127 evaluable; 52.8% clinical response; metabolomic signatures identified

Dimension	Score	Rationale
Scientific Novelty	7	Plasma metabolomics as immunotherapy biomarker in NSCLC is a novel and underexplored approach
Clinical Relevance	6	Biomarker for ICI response prediction is high-value; discovery-stage
Population Reach	7	NSCLC is the most common cause of cancer death globally
Implementation Speed	4	Metabolomic profiling is not yet routine; validation and regulatory pathway needed
Evidence Strength	5	Prospective cohort, n=94–127; single center; discovery-stage; no external validation

Key quantitative result: 52.8% clinical response rate; specific metabolomic signature performance metrics not in abstract
Main limitation: Small single-center cohort; discovery study; metabolomic signatures need prospective validation; platform standardization issues
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.8

Article 22 — Kidane et al. — AATS 2026 Revised Recommendations for Early-Stage NSCLC | PMID 42790620

Expert consensus document; staging and multidisciplinary management

Dimension	Score	Rationale
Scientific Novelty	4	Revision of existing consensus; emphasizes molecular diagnostics and MDT
Clinical Relevance	7	Directly informs surgical and oncologic management of the most common cancer killer
Population Reach	8	Early-stage NSCLC affects hundreds of thousands annually in the US alone
Implementation Speed	7	Guideline documents drive rapid clinical adoption; infrastructure for MDT exists
Evidence Strength	5	Expert consensus; not a primary study; strength depends on underlying evidence synthesis

Main limitation: Consensus document; no new primary data; specific recommendations not detailed in abstract
Evidence Maturity: Validated (consensus-level; not experimental)
Original triage_score: 6 | Phase 2 composite: 6.5

Article 23 — Sumi et al. — PD-L1 and early progression on osimertinib in EGFR+ NSCLC | PMID 42790325

n=370; median PFS 22.9 months, OS 58 months; PD-L1 high → aOR 2.98 for early progression

Dimension	Score	Rationale
Scientific Novelty	6	PD-L1 as a predictor of early osimertinib failure is a clinically useful, underexplored finding
Clinical Relevance	7	Identifies a subgroup (PD-L1 high + de novo Stage IV) that may need intensified therapy upfront
Population Reach	7	EGFR-mutant NSCLC ~10–15% of all NSCLC in Western populations; higher in Asian populations
Implementation Speed	6	PD-L1 testing is routine; this is a re-analysis of existing data that could inform current practice
Evidence Strength	6	Cohort study, n=370; adjusted OR with CIs; retrospective design with confounding risk

Key quantitative result: PD-L1 high + de novo Stage IV: aOR 2.98 (95% CI 1.36–6.xx) for early progression
Main limitation: Retrospective cohort; confounding possible; de novo vs. recurrent disease heterogeneity
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 6.4

Article 24 — Palmer — GLP-1RA-associated hepatotoxicity | PMID 42791090

31 case reports; hepatocellular pattern predominant

Dimension	Score	Rationale
Scientific Novelty	6	GLP-1RA hepatotoxicity is an emerging safety signal; case series provides early signal characterization
Clinical Relevance	7	GLP-1RAs are prescribed to tens of millions; hepatotoxicity signal has immediate pharmacovigilance value
Population Reach	9	GLP-1RA use is now among the most widespread drug classes globally
Implementation Speed	8	Safety signal can be communicated immediately; liver monitoring guidance can be issued now
Evidence Strength	4	31 case reports; no denominator; causality not established; medium confidence; observational

Key quantitative result: 31 cases identified; hepatocellular pattern predominant; cholestatic/mixed also reported
Main limitation: Case reports only; no control group; ascertainment bias; causality not established
Equity: GLP-1RAs are prescribed across diverse populations; signal affects all users
Evidence Maturity: Exploratory (confirmed; signal-level only)
Original triage_score: 6 | Phase 2 composite: 6.5

Article 25 — Lin et al. — Sleep disturbances and suicide risk in dementia, nationwide cohort | PMID 42790647

n=85,920; 2,325 suicide events; sleep disturbance → elevated risk beyond depression

Dimension	Score	Rationale
Scientific Novelty	6	Sleep-dementia-suicide linkage beyond depression is mechanistically novel and clinically important
Clinical Relevance	8	Dementia suicide risk is under-recognized; sleep as modifiable target has immediate clinical utility
Population Reach	8	~55 million people globally with dementia; sleep disturbances affect a large proportion
Implementation Speed	7	Sleep screening in dementia care is feasible and low-cost; can be adopted rapidly
Evidence Strength	6	Nationwide cohort, n=85,920; large and well-powered; residual confounding possible; Taiwan database

Key quantitative result: 2,325 suicide events among 85,920; 645 in sleep-disturbed group; association persisted after accounting for depression
Main limitation: Single-country database (Taiwan); unmeasured confounding; retrospective; causality not established
Equity: Dementia disproportionately affects women and lower-income populations; sleep screening is low-cost 🟡
Evidence Maturity: Exploratory → trending Validated (large national cohort; statistically robust)
Original triage_score: 6 | Phase 2 composite: 7.0

Article 26 — Silberzweig & Garg — GLP-1RAs in Hidradenitis Suppurativa | PMID 42790605

Narrative review; database associations with reduced CV events in HS

Dimension	Score	Rationale
Scientific Novelty	6	GLP-1RAs for HS is a genuinely novel off-label indication with plausible mechanism
Clinical Relevance	6	HS is debilitating and undertreated; GLP-1RA dual benefit (metabolic + skin) is compelling
Population Reach	5	HS affects ~1% of the population; significant unmet need
Implementation Speed	5	GLP-1RAs are available; off-label use is possible but RCT evidence is absent
Evidence Strength	4	Narrative review of database associations; no primary trial data; causal inference limited

Main limitation: Narrative review; no RCT data; database associations are hypothesis-generating
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 5.4

Article 27 — Nakano et al. — Romosozumab in patients ≥85 years, real-world cohort | PMID 42789080

n=337 (of 417 enrolled); equivalent BMD response ≥85 vs. <85 years

Dimension	Score	Rationale
Scientific Novelty	6	Pivotal trials excluded ≥85s; real-world efficacy equivalence in this group is genuinely novel
Clinical Relevance	7	Directly challenges age-based prescribing hesitancy; immediate practice implication
Population Reach	6	The ≥85 cohort is growing rapidly; osteoporotic fracture burden is highest in this group
Implementation Speed	7	Romosozumab is approved; this data supports existing prescribing patterns being extended to very elderly
Evidence Strength	5	Real-world cohort, n=337; no randomization; confounding possible; single-region (Northern Japan)

Key quantitative result: Equivalent 12-month LS-BMD % change in ≥85 vs. <85 years
Main limitation: Non-randomized; single region; functional outcomes and fracture data not reported in abstract
Equity: Very elderly patients are systematically excluded from trials — this study addresses that gap 🟡
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 6.2

Article 28 — Gleeson et al. — Upadacitinib for palmoplantar pustulosis (JAKPPPOT) | PMID 42791196

n=20; all feasibility criteria met; adherence 95.7%

Dimension	Score	Rationale
Scientific Novelty	7	JAK inhibitor in PPP is novel; very limited treatment options exist for this rare, disabling condition
Clinical Relevance	6	High unmet need; feasibility met; efficacy signal pending full trial
Population Reach	3	PPP is rare (estimated <1% of population)
Implementation Speed	5	Upadacitinib is approved for other indications; PPP would need dedicated approval
Evidence Strength	5	Open-label feasibility study, n=20; no blinding; historical control comparison only

Key quantitative result: 19/20 participants achieved ≥80% adherence; mean 95.7% days covered
Main limitation: Tiny n (20); open-label; historical controls; efficacy not the primary endpoint
Evidence Maturity: Exploratory (confirmed; feasibility only)
Original triage_score: 6 | Phase 2 composite: 5.2

Article 29 — Bergamini et al. — 3D skin models for genodermatoses gene therapy | PMID 42790161

In vitro review; 3D scaffolds for rare inherited skin disorders

Dimension	Score	Rationale
Scientific Novelty	6	3D skin models enabling gene therapy testing for rare monogenic skin diseases is frontier
Clinical Relevance	3	In vitro platform; no patient benefit established yet
Population Reach	2	Rare monogenic skin conditions; very small patient populations
Implementation Speed	3	Long pipeline from 3D model to clinical gene therapy
Evidence Strength	3	In vitro review; cannot exceed 5 on Clinical Relevance

Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 3.5

Article 30 — Corona et al. — Epigenetics in Pediatric MS (PEDIGREE) | PMID 42789917

55 differentially methylated regions; EBV and immune networks implicated

Dimension	Score	Rationale
Scientific Novelty	7	Distinct epigenetic signature in early pediatric MS; convergence on regulatory hubs is a novel mechanistic finding
Clinical Relevance	4	Mechanistic discovery; no treatment implication yet; early biomarker potential
Population Reach	4	Pediatric MS is rare (~5% of all MS cases); relevant to MS broadly if validated
Implementation Speed	3	Basic science to clinical application is 5–10+ years
Evidence Strength	5	Multi-center observational; methylation study; medium confidence; no sample size stated

Key quantitative result: 55 DMRs, 28 affecting promoter regions; EBV and immune network involvement
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 composite: 4.6

Article 31 — Zhang et al. — Surgical safety of perioperative ICIs in CRC, protocol | PMID 42790910

Protocol for systematic review; no results

Dimension	Score	Rationale
Scientific Novelty	5	Important safety question; protocol only
Clinical Relevance	5	Anastomotic leakage with perioperative ICIs is a real clinical concern
Population Reach	6	CRC is the second most common cancer cause of death
Implementation Speed	2	Protocol; results years away
Evidence Strength	2	Protocol publication

Evidence Maturity: Exploratory (pre-results)
Original triage_score: 5 | Phase 2 composite: 4.2

Article 32 — Cahill et al. — STRONG trial protocol (blueberries + protein + exercise for frailty) | PMID 42790922

RCT protocol; no results

Dimension	Score	Rationale
Scientific Novelty	5	Novel combination (blueberry polyphenols + protein + exercise); frailty-CV link is understudied
Clinical Relevance	5	Frailty reduction has broad clinical implications; protocol only
Population Reach	7	Frailty affects ~10% of community-dwelling older adults globally
Implementation Speed	2	Protocol; results years away
Evidence Strength	2	Protocol publication

Evidence Maturity: Exploratory (pre-results)
Original triage_score: 5 | Phase 2 composite: 4.2

Article 33 — Zhou et al. — Urinary cfDNA Fragmentomics for urologic cancer detection | PMID 42789091 🔴

AUC 0.98 bladder CA, 0.93 kidney CA; may reduce unnecessary prostate biopsies

Dimension	Score	Rationale
Scientific Novelty	8	Urinary cfDNA fragmentomics (uFRAGMA) applying methylation inference to a non-invasive sample is a technically novel and clinically important approach
Clinical Relevance	7	Bladder and kidney cancer detection via urine is minimally invasive; prostate biopsy reduction is directly actionable
Population Reach	7	Bladder (~~80,000 US cases/year), kidney (~~80,000), and prostate cancer combined affect hundreds of thousands annually
Implementation Speed	4	Requires clinical validation, standardization, regulatory approval; 3–5+ years
Evidence Strength	5	Observational; medium confidence; sample size not stated in abstract; AUC 0.98 for bladder is very high and needs prospective validation

Key quantitative result: Bladder CA AUC=0.98; Kidney CA AUC=0.93; prostate biopsy reduction potential
Main limitation: Observational design; sample size not reported; AUCs from training/test sets unclear; prospective multi-center validation absent
Equity: Non-invasive urine test could reduce barriers to cancer screening, particularly for patients who decline biopsy
Evidence Maturity: Exploratory (confirmed; high AUCs require prospective validation)
Original triage_score: 5 | Phase 2 composite: 6.2

Article 34 — Meroueh et al. — DL distinguishes ASH from MASH on H&E slides | PMID 42787752

AUC 0.86 ± 0.01; balanced accuracy 0.80

Dimension	Score	Rationale
Scientific Novelty	6	AI distinguishing ASH from MASH on routine histology is clinically novel; this is a significant unmet diagnostic challenge
Clinical Relevance	6	ASH vs. MASH distinction affects treatment and prognosis; current standard requires alcohol history
Population Reach	6	MASH affects ~38 million in US; ASH is a major cause of liver disease
Implementation Speed	5	Whole-slide imaging infrastructure growing; regulatory approval needed
Evidence Strength	5	Cohort study; AUC 0.86; balanced accuracy 0.80; sample size not stated; abstract-only

Key quantitative result: AUC 0.86 ± 0.01; balanced accuracy 0.80 on test set
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 5 | Phase 2 composite: 5.6

Article 35 — Yucel et al. — Circadian timing of chemoimmunotherapy in ES-SCLC | PMID 42788839

n=107; earlier treatment timing associated with longer PFS

Dimension	Score	Rationale
Scientific Novelty	7	Chronotherapy for ICI in SCLC is an emerging, hypothesis-generating concept with mechanistic plausibility
Clinical Relevance	5	If validated, would require only scheduling changes; but current evidence is observational
Population Reach	5	ES-SCLC affects ~30,000 patients/year in the US; all have poor prognosis
Implementation Speed	4	Scheduling changes would be low-cost if confirmed; prospective RCT needed first
Evidence Strength	4	Cohort study, n=107; observational; confounding by treatment center, schedule availability, and patient factors

Key quantitative result: Pre-median ToDA treatment: PFS 9.07 vs. [control value not in abstract]
Main limitation: Small observational cohort; major confounding risk; median PFS comparator value truncated in abstract
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 5 | Phase 2 composite: 5.0

Article 36 — Li et al. — NPAR and diabetic kidney disease progression | PMID 42789323

n=305 biopsy-confirmed DKD; NPAR correlates with pathological severity

Dimension	Score	Rationale
Scientific Novelty	5	Inflammatory biomarker ratios in DKD is well-explored territory; NPAR adds modest novelty
Clinical Relevance	5	Prognostic biomarker; could inform monitoring intensity but not treatment-changing
Population Reach	7	DKD affects ~40% of diabetic patients; ~37 million with diabetes in US
Implementation Speed	6	Neutrophil count and albumin are routine labs; NPAR calculated easily
Evidence Strength	5	Retrospective, n=305; biopsy-confirmed which is a strength; single institution

Key quantitative result: Higher NPAR quartiles significantly associated with renal dysfunction and advanced pathological lesions
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 5 | Phase 2 composite: 5.5

Article 37 — Thorne et al. — RNA thermogenic therapy during GLP-1 weight loss (PNAS) | PMID 42789307

RNA-based therapy to preserve lean mass and enhance thermogenesis

Dimension	Score	Rationale
Scientific Novelty	8	RNA thermogenic co-therapy with GLP-1RA is a genuinely novel mechanistic approach to a major clinical problem (lean mass loss)
Clinical Relevance	4	Preclinical/observational; unknown species; no human data
Population Reach	9	GLP-1RA use is globally massive; lean mass loss affects all users
Implementation Speed	2	Early-stage; RNA delivery, safety, and regulatory pathway are years away
Evidence Strength	3	Unknown species/model; medium confidence; no clinical data; cannot exceed 5 on Clinical Relevance

Main limitation: Unknown species model; no human data; lean mass loss during GLP-1 therapy is a real problem but this is preclinical
Evidence Maturity: Exploratory (confirmed)
Original triage_score: 5 | Phase 2 composite: 5.3

Article 38 — Bruggisser et al. — Circadian rhythm-aligned training in older adults (RCT) | PMID 42791208

n=93 analyzed; no clinically meaningful benefit from timing-aligned training

Dimension	Score	Rationale
Scientific Novelty	5	Well-designed null result; adds to circadian exercise timing literature
Clinical Relevance	5	Null result: timing of resistance training doesn't matter clinically in older adults; simplifies guidance
Population Reach	7	Sarcopenia affects ~10–15% of older adults globally
Implementation Speed	8	Null result immediately actionable: no need for complex timing protocols
Evidence Strength	7	RCT, n=93, mean age 67; clear primary and secondary endpoints; rigorous design

Key quantitative result: No significant benefit from diurnal timing-aligned training (null result)
Evidence Maturity: Validated (well-designed RCT with clear null finding)
Original triage_score: 5 | Phase 2 composite: 6.0

Article 39 — Rooha et al. — M-MCST midlife metacognitive strategy training feasibility | PMID 42789559

7-session program; participants found design promising

Dimension	Score	Rationale
Scientific Novelty	5	Metacognitive strategy training is established; midlife adaptation is incremental
Clinical Relevance	3	Feasibility study only; no outcome data
Population Reach	6	Cognitive aging affects a large and growing population
Implementation Speed	4	Program design complete but efficacy unproven
Evidence Strength	3	Feasibility/observational; medium confidence; no outcome measures

Evidence Maturity: Exploratory (confirmed)
Original triage_score: 5 | Phase 2 composite: 4.3

Article 40 — Patel et al. — Aortic Stenosis review (AFP) | PMID 42789638

TAVR = surgical AVR in mortality; AS affects 3.7% of population

Dimension	Score	Rationale
Scientific Novelty	3	TAVR-surgical equivalence is established; this is a primary care review summary
Clinical Relevance	6	Useful for primary care clinicians recognizing and referring AS; broad audience
Population Reach	7	AS affects 3.7% of US population; highly prevalent
Implementation Speed	7	Primary care review immediately actionable for clinical awareness
Evidence Strength	4	Review/observational summary; medium confidence; no new data

Evidence Maturity: Validated (consolidated known evidence)
Original triage_score: 5 | Phase 2 composite: 5.5

Article 41 — Sarah et al. — Primary lymphoma of the breast case report | PMID 42787887

Single case; tissue biopsy and immunophenotyping essential

Dimension	Score	Rationale
Scientific Novelty	2	Case report of a known entity; no new findings
Clinical Relevance	3	Reinforces established diagnostic approach; educational value only
Population Reach	1	<0.5% of breast malignancies
Implementation Speed	3	Educational; immediate for awareness
Evidence Strength	2	Single case report

Evidence Maturity: Exploratory (confirmed)
Original triage_score: 4 | Phase 2 composite: 2.3

Phase 3 Ranking

Conflict Note

Two articles address the same therapeutic space (RRMM) from different angles: Article 1 (EXCALIBER-RRMM, iberdomide) and Article 11 (CEPHEUS subgroup, DVRd). They are not directly conflicting — they address different lines of therapy and drug combinations — but together they reinforce the movement toward quadruplet/triplet CELMoD or anti-CD38 combinations in myeloma.

Two articles address safety of GLP-1RAs from different angles: Article 24 (hepatotoxicity signal) is a caution, while the GLP-1RA class is broadly positioned as beneficial across multiple conditions (Articles 26, 37). No direct contradiction; the hepatotoxicity data is signal-level only.

Phase 3 Composite Impact Scores

Weighting: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%

Rank	Article #	PMID	Short Title	Flag	Impact Score	Clin Rel (30%)	Pop Reach (25%)	Sci Nov (20%)	Impl Speed (15%)	Evid Str (10%)	Triage Score	Study Design	Rank Justification
1	25	42790647	Sleep disturbances & suicide in dementia	⬜	7.15	8	8	6	7	6	6	Nationwide cohort	Large national cohort (n=85,920) with a clinically actionable, immediately implementable finding: sleep disturbances in dementia patients predict elevated suicide risk independently of depression. Sleep screening is low-cost and feasible in any dementia care setting. This result has immediate practice implications for a growing, underserved population.
2	11	42789828	DVRd sustained MRD negativity in transplant-ineligible NDMM	⚪	7.10	8	7	6	6	7	6	Phase 3 subgroup	Pre-specified subgroup of a Phase 3 RCT showing DVRd nearly doubles sustained MRD negativity at both 12 and 24 months in transplant-ineligible NDMM — a high-unmet-need population. MRD negativity is emerging as a clinically meaningful endpoint and these data support intensification with daratumumab in this vulnerable group.
3	1	42790445	EXCALIBER-RRMM: Iberdomide + daratumumab + dex	⚪	7.05	8	7	7	6	8	7	Phase 3 RCT	The largest-enrollment article in this batch (939 randomized) and the only fully powered phase 3 RCT. Iberdomide represents a mechanistically distinct class (CELMoD) from standard IMiDs; head-to-head vs. DVd in 1–2 prior lines RRMM is a practice-shaping design. Abstract-only limits full scoring, but evidence strength is among the highest in this batch.
4	6	42790417	Clobetasol for oral cGVHD RCT	⚪	6.80	8	5	6	8	6	7	Phase 2 RCT	A 91% overall response rate with a topical off-the-shelf corticosteroid (clobetasol solution) for oral cGVHD is a compelling result. The high implementation speed score reflects that this is an approved, inexpensive, widely available agent. The population is smaller but the unmet need within post-HSCT cGVHD is substantial, and the result could be adopted rapidly pending Phase 3 confirmation.
5	24	42791090	GLP-1RA hepatotoxicity	⚪	6.65	7	9	6	8	4	6	Case series	GLP-1RAs are now among the most widely prescribed drug classes globally. Thirty-one cases of hepatotoxicity — predominantly hepatocellular — represent a meaningful pharmacovigilance signal. Despite weak evidence (case reports, no denominator), population reach and implementation speed (liver monitoring guidance can be issued immediately) justify this ranking.
6	8	42791219	PRP vs. Collagen vs. HA in knee OA	⚪	6.55	7	9	5	6	6	7	RCT	Knee OA is one of the highest-burden conditions globally. This RCT adds head-to-head comparative data for three intra-articular options including hydrolyzed collagen. Limited by lack of between-group superiority data in the abstract, but population reach and clinical relevance are both very high.
7	10	42787875	Chemoradiotherapy survival benefit in limited-stage MCL	⚪	6.45	7	4	6	6	5	6	NCDB cohort	The ~3.8-year OS advantage for combined modality therapy in limited-stage MCL (11.2 vs. 7.4 years) is clinically substantial. MCL is rare, limiting population reach, but the disease is nearly always fatal and data in this stage are extremely sparse. The NCDB design limits causal inference but the magnitude of benefit warrants clinical attention.
8	22	42790620	AATS 2026 Revised Guidelines for Early-Stage NSCLC	⚪	6.40	7	8	4	7	5	6	Consensus	Updated multidisciplinary management guidelines for the most lethal cancer. Consensus documents drive rapid adoption across thoracic surgical programs globally. High population reach and implementation speed; lower novelty as guidelines synthesize existing data.
9	23	42790325	PD-L1 predicts early osimertinib failure in EGFR+ NSCLC	⚪	6.35	7	7	6	6	6	6	Cohort	Identifying that PD-L1 high + de novo Stage IV EGFR-mutant NSCLC carries nearly 3-fold higher early progression risk on osimertinib has direct implications for upfront treatment intensification decisions — a clinically valuable insight using routinely available data.
10	33	42789091	Urinary cfDNA fragmentomics for urologic cancers	🔴	6.30	7	7	8	4	5	5	Observational	AUC of 0.98 for bladder cancer and 0.93 for kidney cancer via urine-only testing is a remarkable technical achievement. Scientific novelty is high. However, the lack of sample size reporting and absence of prospective validation cap the evidence strength, and implementation is at least 3–5 years away. The early detection flag is well-earned.
11	13	42789831	CNPI-BCS for breast cancer screening equity	🔴	6.25	6	8	5	7	5	6	Cohort	A community-need index that directs screening resources toward highest-need census tracts is immediately actionable for cancer centers with community outreach obligations. Population reach is high; AUC of 0.692 is adequate for resource allocation; equity implications are the strongest asset of this study.
12	27	42789080	Romosozumab equivalent efficacy in ≥85 years	⚪	6.20	7	6	6	7	5	6	Real-world cohort	Filling a critical evidence gap for the oldest old — a group systematically excluded from pivotal trials — this real-world study supports not withholding romosozumab on age alone. High implementation speed because this changes clinical decision-making with an already-approved drug.
13	5	42790835	IBS-like symptoms in quiescent IBD meta-analysis	⚪	6.15	7	7	5	6	5	7	Meta-analysis of RCTs	Persistent IBS-like symptoms in IBD remission affect millions and are not addressed by anti-inflammatory therapy. Meta-analysis of 13 RCTs is the right design, but extreme heterogeneity (I²=90%) and very low certainty evidence limit actionability despite broad clinical relevance.
14	15	42791089	AI coronary analysis in ED, multicenter	⚪	6.10	7	8	5	6	6	6	Multicenter cohort	NPV of 95.4% for obstructive CAD in the ED using AI-assisted CCTA is clinically useful for rule-out. Multicenter design and large n (1,193) improve confidence. Sensitivity of 79.5% is a limitation. Population reach (chest pain is among the most common ED complaints) is the key strength.
15	4	42791198	CAR-T in glioma meta-analysis	🟠	5.85	6	5	7	3	6	7	Meta-analysis	Despite its 🟠 flag and scientific novelty (CAR-T in CNS), the small pooled n (153), wide CIs on ORR (8–32%), and extreme implementation barriers keep this at rank 15. GBM remains a major unmet need and the CR rate of 8.1% is meaningful in this disease context, but the evidence base remains very early.
16	38	42791208	Circadian training timing — null RCT	⚪	5.80	5	7	5	8	7	5	RCT	Well-conducted RCT with a clear, clinically useful null result: no meaningful benefit to timing resistance training by circadian rhythm in older adults. High evidence strength and immediate implementation value (simplifies prescription guidance) offset limited novelty.
17	21	42791035	METLUNG plasma metabolomics for NSCLC immunotherapy	⚪	5.75	6	7	7	4	5	6	Cohort	Metabolomic profiling as an ICI biomarker is genuinely novel and NSCLC is a high-reach disease. But discovery-stage data from a single small cohort limits actionability. Worth watching as this approach matures.
18	19	42790448	Lancet Oncology Commission on Equitable Cancer Genomics	⚪	5.75	7	9	5	4	4	6	Commission	Global reach and explicit equity focus are compelling, but a commission report without primary trial data is policy advocacy, not clinical evidence. Still, the framing of millions denied guideline-indicated care annually is a powerful call for systemic change.
19	12	42789169	BCI-robot vs. conventional stroke rehab NMA	⚪	5.70	6	8	6	3	6	6	NMA	BCI-coupled robotics is exciting technology and stroke rehabilitation is a massive population need. However, BCI-robot showed no clear superiority to conventional therapy in this NMA, and implementation barriers are significant. Worth tracking as technology matures.
20	2	42790934	CBC+CPD ML model for NHL triage	⚪	5.65	6	5	5	6	5	7	Cohort	A practical machine learning triage tool using already-collected CBC parameters for NHL inpatients. The AUC degradation from training (0.894) to validation (0.803) and lack of external validation are notable. CPD parameters are not universally reported by all analyzers, limiting immediate generalizability.
21	37	42789307	RNA thermogenic therapy during GLP-1 weight loss	⚪	5.50	4	9	8	2	3	5	Preclinical/observational	Conceptually important for an enormous population (GLP-1RA users experiencing lean mass loss). Scientific novelty is high. But unknown species model and lack of human data cap clinical relevance, and translation is at minimum 5–10 years. A strong watchlist item.
22	34	42787752	DL distinguishes ASH from MASH on H&E	⚪	5.45	6	6	6	5	5	5	Cohort	AI distinguishing two histologically similar liver diseases is clinically useful. AUC 0.86 on standard pathology slides is a meaningful performance metric. Needs prospective validation and WSI infrastructure.
23	20	42790332	PD-L1 vs. 5-variable genomic score — null result	⚪	5.45	6	7	5	5	5	6	Cohort	Null result: the composite genomic score adds nothing over PD-L1 alone. This simplifies biomarker strategy and is informative for clinical practice, though the small efficacy cohort (n=102) limits confidence.
24	7	42789934	ADAMTS13 variant database for cTTP	⚪	5.35	6	3	6	8	5	7	Database/observational	Immediately accessible, free, curated online resource for a rare but life-threatening disease. High implementation speed and directly useful for variant interpretation. Limited by the rarity of cTTP (low population reach).
25	26	42790605	GLP-1RAs in hidradenitis suppurativa	⚪	5.35	6	5	6	5	4	6	Narrative review	GLP-1RAs for HS are a compelling hypothesis with plausible dual mechanism (metabolic + anti-inflammatory). But narrative review of database associations is hypothesis-generating only. RCT data are needed before adoption.
26	36	42789323	NPAR and diabetic kidney disease	⚪	5.30	5	7	5	6	5	5	Retrospective cohort	Simple inflammatory ratio (neutrophil-to-albumin) correlates with DKD severity. Easy to calculate from routine labs. But a retrospective single-center cohort without external validation and without treatment-changing implications limits impact.
27	3	42789168	Habitat imaging CT/PET-CT systematic review	⚪	5.20	5	6	6	4	6	7	Systematic review	Comprehensive synthesis of habitat imaging across 21 studies and 7,363 patients. Authors themselves note prospective validation is needed. Clinically interesting concept but not yet practice-ready.
28	9	42788264	TCM + HIFU for adenomyosis pilot RCT	⚪	5.15	5	6	6	4	5	7	Pilot RCT	Pain reduction in adenomyosis is meaningful, and combining TCM with HIFU is novel. Small pilot study with significant methodological limitations prevents stronger recommendation. HIFU access remains restricted.
29	30	42789917	Epigenetic signature in pediatric MS	⚪	4.55	4	4	7	3	5	6	Observational	Scientifically interesting mechanistic finding linking EBV, DNA methylation, and immune networks in pediatric MS. Currently a discovery-stage finding with no direct clinical implication. Worth monitoring as the PEDIGREE study continues.
30	35	42788839	Circadian timing of chemoimmunotherapy in ES-SCLC	⚪	4.55	5	5	7	4	4	5	Cohort	Chronotherapy is a genuinely novel concept and the circadian biology rationale is sound. But n=107 observational data with truncated PFS comparator data in the abstract are insufficient. Needs RCT before any practice change.
31	28	42791196	Upadacitinib for palmoplantar pustulosis feasibility	⚪	4.50	6	3	7	5	5	6	Feasibility RCT	High unmet need in PPP and strong adherence signal are positives. Tiny n (20) and feasibility-only design limit impact. The signal justifies a full RCT, which this study was designed to enable.
32	40	42789638	Aortic stenosis: diagnosis and treatment (AFP)	⬜	4.45	6	7	3	7	4	5	Review	Well-written primary care review. High population reach and immediate utility for family physicians. No new data; limited scientific novelty.
33	17	42790865	Predictive factors for functional recovery in older inpatients	⚪	4.40	6	7	4	5	5	6	Retrospective	Large retrospective cohort in geriatric rehabilitation. Multivariable models improve prediction. Inconsistent biomarker associations limit clinical adoption.
34	31	42790910	Perioperative ICI safety in CRC — protocol	⚪	4.25	5	6	5	2	2	5	Protocol	Important question (anastomotic leakage risk with perioperative ICIs in CRC) but no data yet. Watchlist.
35	32	42790922	STRONG trial protocol (blueberries + protein + exercise)	⚪	4.25	5	7	5	2	2	5	Protocol	Novel multimodal lifestyle intervention for frailty; no results. Watchlist.
36	39	42789559	M-MCST midlife metacognitive training feasibility	⚪	4.10	3	6	5	4	3	5	Feasibility	Promising program design for cognitive aging; no efficacy data yet.
37	14	42787768	Weakly supervised 3D medical image segmentation	⚪	3.75	4	3	6	3	3	6	Computational	Technical computer vision paper; no clinical population; no patient outcomes.
38	16	42790900	AI in perioperative pain — scoping review protocol	⚪	3.65	4	6	4	2	2	6	Protocol	Protocol for a scoping review. No results.
39	29	42790161	3D skin models for genodermatoses gene therapy	⚪	3.50	3	2	6	3	3	6	In vitro review	Technically interesting but very early preclinical; tiny disease populations.
40	18	42790864	LncRNAs and cancer epitranscriptome	⚪	3.25	3	2	6	2	3	6	Mechanistic review	Basic science review; no patient data; very long horizon to clinical impact.
41	41	42787887	Primary lymphoma of the breast — case report	⬜	2.30	3	1	2	3	2	4	Case report	Single case report; known entity; educational value only.

Deep dive 1 Iberdomide Plus Daratumumab Phase 3 Trial PMID 42790445 ↗

[HOOK]

Multiple myeloma is the second most common blood cancer — and despite decades of progress, it almost always comes back. When it does, each relapse is typically harder to treat than the last. For patients who have been through one or two rounds of treatment and seen their disease return, the question isn't just what comes next — it's what will actually work. The EXCALIBER-RRMM trial may be answering that question with a new kind of drug.

[THE DISCOVERY]

Researchers from an international team led by Sagar Lonial and colleagues published results of a phase 3 randomized trial comparing a new drug combination — iberdomide plus daratumumab and dexamethasone — against the established standard of daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma after one to two prior lines of therapy. Published in The Lancet Oncology, the trial enrolled 939 patients across two stages, making it one of the larger myeloma studies of recent years. The headline: iberdomide-based therapy is being tested head-to-head against one of the best existing regimens in this setting.

[THE SCIENCE BEHIND IT]

Iberdomide belongs to a class called CELMoDs — cereblon E3 ligase modulators — which work through the same molecular pathway as older immunomodulatory drugs like lenalidomide and pomalidomide, but with a more potent and selective mechanism. Think of it as a more precise version of a lock-picker: it targets and degrades specific proteins that myeloma cells depend on, while also revving up the immune system's T cells and natural killer cells more effectively. The trial used an open-label, randomized, controlled phase 3 design — the gold standard for clinical evidence — with 939 patients randomized across multinational sites. Classification confidence is high. The primary limitation is that we are working from an abstract only; the critical primary endpoint data (progression-free survival) and subgroup analyses are not yet publicly available in full.

[WHO THIS HELPS]

This trial targets adults with relapsed or refractory multiple myeloma after one or two prior lines of therapy — a substantial population. Globally, approximately 176,000 new myeloma cases are diagnosed each year, and the vast majority will eventually relapse. The 1–2 prior line window is particularly important: patients are still fit enough to tolerate intensive combination therapy, and durable remissions achieved at this stage have the best chance of meaningfully extending life. The trial enrolled participants across Europe, Asia, and the Americas, suggesting a geographically diverse evidence base, though full demographic reporting will await publication.

[THE REAL-WORLD IMPACT]

If the full trial data confirm superiority of the iberdomide-containing regimen, this could shift the standard of care for second- or third-line myeloma. Iberdomide could position itself as the preferred partner for daratumumab — displacing bortezomib-based triplets — in patients who have already been exposed to IMiDs. That would be a meaningful change: it would introduce a novel drug class into earlier lines of therapy, potentially preserving other agents for later. The open-label design and bortezomib-resistance landscape will need to be addressed in the full publication.

[WHAT WE STILL DON'T KNOW]

The abstract does not report primary endpoint results. We don't know whether progression-free or overall survival was significantly improved, what the response rates were, or how the safety profile of iberdomide-daratumumab compares to DVd in terms of infections, cytopenias, or dose modifications. Without that data, ranking the clinical magnitude of this trial's finding is premature. The open-label design also means physician behavior could influence response assessments.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: High — Phase 3 RCT with rigorous design, high classification confidence, multinational enrollment
Translation Speed: Near-term (1–3 years pending full data and regulatory review; iberdomide is in active development pipeline)
Barrier Analysis:
- Regulatory: FDA/EMA review required; iberdomide not yet approved
- Reimbursement: CELMoDs will likely face payer scrutiny comparable to pomalidomide
- Cost: Combination regimens in myeloma are expensive; access in low/middle-income countries will be limited
- Awareness: Oncology community is closely watching this readout; rapid uptake anticipated if data support superiority
- Equity: Multinational enrollment is encouraging, but global access to novel biologics remains profoundly unequal — a concern the Lancet Oncology Commission (Casolino et al.) highlights in this same batch

[CALL TO ACTION / CLOSING]

Iberdomide may represent the next evolution in myeloma treatment — but the real story will be told when the full progression-free survival data are published. This is the trial to watch in relapsed myeloma over the next twelve months.